Whats the Role of Weight Loss Pharmacotherapy in Obesity Management?

Activity Overview and Format

Release Date: July 1, 2020
Expiration Date: July 31, 2021

Primary care providers (PCPs) benefit from continuing education on current treatment recommendations for insulin therapy by learning how to support optimal type 2 diabetes (T2D) management. Clinicians should understand the contemporary role of insulin therapy in achieving glycemic control in patients with T2D and how its role evolves with disease progression. They should also recognize its role in rapidly achieving control in patients with severe hyperglycemia.

PCPs who treat T2D should be up-to-date on best practices for choosing, initiating, and adjusting insulin therapy as well as current options for monitoring blood glucose and ensuring patient safety during insulin therapy. Current treatment guidelines for T2D recommend an individualized, patient-centered regimen with an emphasis on self-management to improve blood glucose management and treatment adherence.

This activity will include 4 podcasts focusing on the initiation, titration, and management of insulin therapy in patients with T2D, emphasizing the importance of individualizing insulin regimens and avoiding hypoglycemia and weight gain, in accordance with current treatment guidelines.

CME/CE/CPE Information
Daniel Einhorn, MD, FACP, FACE

Daniel Einhorn, MD, FACP, FACE
Medical Director
Scripps Whittier Diabetes Institute
Clinical Professor of Medicine
University of California, San Diego
Clinical Endocrinologist
Diabetes and Endocrine Associates
La Jolla, California

Davida F Kruger, MSN, APN-BC, BC-ADM

Davida F Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner
Division of Endocrinology, Diabetes, and Bone and Mineral Disorders
Henry Ford Health System
Detroit, Michigan

Javier Morales, MD, FACP, FACE

Javier Morales, MD, FACP, FACE
Associate Clinical Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York
Vice President
Principal Clinical Trials Investigator
Advanced Internal Medicine Group
East Hills, New York

Intended Audience

This activity is intended for diabetes-treating PCPs, including physicians, physician assistants, nurses, nurse practitioners, pharmacists, diabetes educators, and other healthcare providers (HCPs) who desire more information on the use of insulin in patients with T2D.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with T2D who are likely to benefit from insulin therapy based on current recommendations, patient and disease characteristics, and treatment goals
  • Discuss strategies to individualized insulin regimens for patients with T2D, considering insulin characteristics in the context of patient needs, goals, and preferences
  • Determine how to appropriately modify insulin therapy on the basis of BG data to safely achieve individualized treatment goals (eg, dose/titrate, intensify, address hypoglycemia)
  • Provide patient education and convey information on therapeutic advances to support safe and successful use of insulin therapy
Continuing Medical Education, Continuing Education, and Continuing Pharmacy Education Accreditation and Credit Designation Statements


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Medical and Nursing Education, Inc. (IMNE), and the Center for Independent Health Education. IMNE is accredited by the ACCME to provide continuing medical education for physicians.

IMNE designates this enduring activity for a maximum of 2.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses/Nurse Practitioners

IMNE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

IMNE designates this educational activity for 2.75 contact hours of continuing education credit (2.75 CEUs). Accreditation by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

Certified Diabetes Educators
ANCC-accredited providers have been approved by the National Certification Board for Diabetes Educators (NCBDE) as providers of continuing education (CE). Individuals seeking recertification from the NCBDE can use the CE contact hours received through their participation in this activity.


Center for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center for Independent Healthcare Education has assigned 2.75 contact hours (2.75 CEUs) of continuing pharmacy education credits for participating in this activity.

ACPE UAN: 0473-9999-20-004-H01-P

Activity type: knowledge-based

For questions regarding pharmacy accreditation of this activity, please contact us at info@jointsponsor.com.


It is the policy of IMNE and the Center to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in planning (eg, faculty, CME/CE provider staff, and educational partner staff) are expected to disclose any significant financial relationships with commercial interests over the past 12 months. It is also required that faculty identify and reference off-label product or investigational uses of pharmaceutical agents and medical devices.

All staff of IMNE and the Center in a position to influence content have filed statements of disclosure with the continuing education provider. Any conflicts of interest were identified and resolved prior to their involvement in planning this activity. These disclosures are available for review by contacting Steve Weinman at 1 908 360 4555 or steve.weinman@imne.com.

Resolutions of conflict of interest have been made in the form of external peer review.

The following disclosures have been made:


Daniel Einhorn, MD, FACP, FACE
Consultant: Abbott, Lilly, Novo Nordisk, Sanofi.
Contracted Research: Lilly, Novo Nordisk, Sanofi, Teva.
Speakers Bureau: Abbott, Lilly, Novo Nordisk, Sanofi.

Davida F Kruger, MSN, APN-BC, BC-ADM
Advisory Boards: Abbott, Boehringer Ingelheim, Dexcom, Janssen, Lilly, Pendulum Therapeutics, Merck, Novo Nordisk, Sanofi.
Grants: Abbott, Dexcom, Helmsley Charitable Trust, Lexicon, Novo Nordisk.
Speakers Bureau: Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Insulet, Janssen, Lilly, Novo Nordisk, Valeritas.
Stock: Pendulum Therapeutics.

Javier Morales, MD, FACP, FACE
Consultant: AstraZeneca, Bayer, Boehringer Ingelheim, Intarcia, Lilly, Novo Nordisk.
Speakers Bureau: AstraZeneca, Boehringer Ingelheim, Lilly, Novo Nordisk.

IMNE Staff

Katie Fidanza
Associate Program Director
Ms Fidanza has nothing to disclose.

Amy Groves
Business Lead
Ms Groves has nothing to disclose.

Sanam Mirza, MD
Medical Writer II
Dr Mirza has nothing to disclose.

Lindsey Sniffen
Program Coordinator
Ms Sniffen has nothing to disclose.

Steve Weinman, MSc, RN
Director of Accreditation
Lead Nurse Planner
Mr Weinman has nothing to disclose.

CME/CE/CPE Reviewers

Martin Quan, MD
Dr Quan has nothing to disclose.

Catherine Lombardi, RN
Ms Lombardi has nothing to disclose.

Paul DeLisle
Mr DeLisle has nothing to disclose.

Vesna Drenovac, RPh, MSc, CHCP
Ms Drenovac has nothing to disclose.


This activity is designed for HCPs for educational purposes. Information and opinions offered by the faculty/presenters represent their own viewpoints. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information.

While IMNE and the Center make every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use. There is no fee to participate in this educational activity.

Privacy and Confidentiality Statement

IMNE will record learners’ personal information as provided on CME/CE/CPE evaluations to allow for issuance and tracking of CME/CE/CPE certificates. IMNE may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME/CE/CPE program. No individual performance data or other personal information collected from evaluations will be shared with third parties.

Commercial Support Acknowledgment

This activity is supported by an educational
grant from Novo Nordisk Inc.

Method of Participation

To receive a maximum of 2.75 AMA PRA Category 1 Credits, 2.75 continuing nursing education contact hours, or 2.75 pharmacy contact hours, participants should note the following:

  • Listen to each of the 4 podcasts
  • Complete the activity posttest and evaluation for each podcast
  • Upon achieving a score of 80% or higher, you will be emailed a CME/CE certificate
  • Pharmacists: Credit will be uploaded to CPE Monitor within 2 weeks of completion of all 4 podcasts

The estimated time to complete this activity, including review of all materials, is 2.75 hours. For questions about the content or obtaining CME/CE credit, please contact Steve Weinman, MSc, RN, at steve.weinman@imne.com. For questions concerning CPE credit contact Vesna Drenovac at vdrenovac@jointsponsor.com.

Minimum System Requirements

The following system requirements are recommended for the best presentation-viewing experience

  • Microsoft Windows 8 or above
  • Display resolution of 1024 × 768 pixels or greater
  • Windows-compatible sound card
  • Microsoft Internet Explorer 10 or above
  • Windows Media Player 11
  • Adobe Reader version 11 or above (http://get.adobe.com/reader/)
  • Broadband Internet connection (512 kbps and above)
  • Macintosh OS X 10.9 or above
  • Display resolution of 1024 × 768 pixels or greater
  • Safari version 8 or above
  • Broadband Internet connection (512 kbps and above)
  • iOS version 10 or above